시장보고서
상품코드
1092722

세계의 펩티드 치료제 시장 규모, 점유율, 동향 분석 : 용도별, 유형별, 제조업체 유형별, 투여 경로별, 합성 기술별, 지역별, 부문별 예측(2022-2030년)

Peptide Therapeutics Market Size, Share & Trends Analysis Report By Application, By Type, By Type of Manufacturers, By Route of Administration, By Synthesis Technology, By Region, And Segment Forecasts, 2022 - 2030

발행일: | 리서치사: Grand View Research, Inc. | 페이지 정보: 영문 85 Pages | 배송안내 : 2-10일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 펩티드 치료제 시장 규모는 2022-2030년 6.4%의 CAGR로 성장하며, 2030년까지 687억 달러에 달할 것으로 예상되고 있습니다.

시장의 주요 촉진요인으로 부작용이 적고 효율적·즉효성 있는 치료제의 요구 및 대체적·저비용 치료제의 연구·도입 요구, 고령자 인구의 증가에 의해 암 및 당뇨병 등 대상 질환의 발생률이 상승하고 있는 것 등을 들 수 있습니다.

세계의 펩티드 치료제 시장을 분석했으며, 시장의 기본 구조 및 주요 촉진·억제요인, 용도별·유형별·제조업체의 유형별·투여 경로별·합성 기술별·지역별 시장 동향 전망, 주요 기업의 개요와 전략 상황 등의 정보를 정리하여 전해드립니다.

목차

제1장 분석 방법·범위

제2장 개요

제3장 펩티드 치료제 시장 : 변동 요인·동향·범위

  • 시장의 내역과 범위
  • 시장 촉진요인 분석
  • 시장 억제요인 분석
  • 우선시되는 주요 기회
  • 펩티드 치료제 시장 : SWOT 분석, 요인별(정치적·법적, 경제적, 기술적)
  • 업계 분석 : Porter의 산업 분석

제4장 펩티드 치료제 시장 : 용도별 추산과 동향 분석

  • 펩티드 치료제 시장 : 용도별 동향 분석
  • 대사
  • 심혈관
  • 호흡기
  • 소화관
  • 항감염증
  • 통증
  • 피부
  • 중추신경계(CNS)
  • 신장
  • 기타

제5장 펩티드 치료제 시장 : 유형별 추산과 동향 분석

  • 펩티드 치료제 시장 : 유형별 동향 분석
  • 제네릭 의약품
  • 신약

제6장 펩티드 치료제 시장 : 제조업체의 유형별 추산과 동향 분석

  • 펩티드 치료제 시장 : 제조업체의 유형별 동향 분석
  • 내제
  • 외주

제7장 펩티드 치료제 시장 : 투여 경로별 추산과 동향 분석

  • 펩티드 치료제 시장 : 투여 경로별 동향 분석
  • 비경구
  • 경구
  • 폐전달
  • 경점막
  • 기타

제8장 펩티드 치료제 시장 : 합성 기술별 추산과 동향 분석

  • 펩티드 치료제 시장 : 합성 기술별 동향 분석
  • 고상 펩티드 합성(SPP)
  • 액상 펩티드 합성(LPP)
  • 하이브리드 기술

제9장 펩티드 치료제 시장 : 지역별 추산과 동향 분석, 원료별·제품별·용도별

  • 펩티드 치료제 시장 : 지역별 시장 점유율(2021년·2030년)
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동·아프리카

제10장 경쟁 구도

  • 전략 프레임워크
  • 시장 참여 상황
  • 기업 개요
    • Bachem Holding AG
    • Eli Lilly and Company
    • Pfizer Inc.
    • Amgen Inc.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical
    • Lonza Inc.
    • Sanofi
    • Bristol-Myers Squibb(BMS)
    • AstraZeneca PLC
    • GlaxoSmithKline(GSK)
    • Novartis AG
    • Novo Nordisk A/S
KSA 22.06.30

Peptide Therapeutics Market Growth & Trends:

The global peptide therapeutics market size is expected to reach USD 68.7 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.4% from 2022 to 2030. Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.

As per the International Agency for Research on Cancer (GLOBOCAN 2020) report, there will be 19,292,789 new cancer cases diagnosed globally in 2020, with 9,958,133 cancer deaths. Furthermore, the five-year prevalence of cancer was projected to be 50,550,287 worldwide. The global number of new cases of cancer is projected to reach 28,887,940 by 2040. As a result, the higher incidence of cancers around the world is set to perform an important role in the development of peptide therapeutics over the forecast period. Besides that, increasing awareness among health care providers and patients about the negative effects of chemotherapy and/or radiation therapy is a primary factor influencing the increased emphasis on alternative therapeutics like peptide-based drugs.

Technological advancements in the peptide manufacturing process are driving the market during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification and automation process and less generation of waste are additional factors contributing to the market growth. For instance, in March 2022, Amgen announced the official opening of its latest bio-manufacturing facility in Holly Springs, North Carolina. The facility, which is set to open in 2025, will help cope with the growth of Amgen's medicines, which treat serious diseases like cancer and heart disease.

The COVID-19 pandemic is anticipated to spur the spectrum of cancer care, which includes delayed diagnoses, therapeutic interventions, and the impeding of clinical trials focused on developing cost-effective therapeutics for cancer treatment, with peptide therapeutics for cancer treatment being no exception, as per a research article published in Nature Cancer, 2020. There have been 21 peptide drugs in therapies for the treatment of COVID-19 as of May 2020, such as 15 synthetic peptides for the therapies of acute respiratory distress syndrome (ARDS) as well as other respiratory illnesses induced by severe acute respiratory infection. However, current implementations of peptide therapeutics in oncological and metabolic disorders and other fields have been hampered by drug shortages, operational problems, and the slow progress of clinical trials involving non-COVID-19 therapeutics.

For instance, in May 2022, EVER Pharma announced that Bortezomib has received EU-wide approval for the treatment of individuals with symptomatic myeloma and mantle cell lymphoma1. In May 2022, The European Commission approved Novartis' Jakavi post-steroid therapy for acute and chronic graft-versus-host ailments. Jakavi will be the first JAK1/2 inhibitor widely available for patients in Europe with steroid-refractory graft-versus-host ailment. In September 2021, Nimble Therapeutics and Incyte entered into strategic collaborative research to discover additional new peptide therapies.

Peptide Therapeutics Market Report Highlights:

  • By application, cancer held the second-largest revenue share in 2021 owing to the increasing demand for alternative therapeutics over conventional treatment options. Peptides are being used as potential therapeutic agents in cancer treatment
  • The generic type segment is expected to showcase an upward shift due to the patent expiration of blockbuster peptides and supportive government initiatives pertaining to the introduction of the generic class
  • By type of manufacturers, the outsourced segment is expected to expand at a lucrative CAGR of 6.6% over the forecast period owing to the requirements of complex procedures and a shift in preference toward outsourcing, which helps in eliminating the cost of production
  • By synthesis technology, hybrid technology is expected to witness the fastest growth over the forecast period. Benefits associated with this technology such as time conservation and ease of usage for both solid- and liquid-phase peptide synthesis are the key factors affirming growth
  • North America held the largest share in terms of revenue in 2021 owing to a higher level of awareness pertaining to genomics and proteomics products, well-established R&D infrastructure, and rising funding initiatives
  • Asia Pacific is expected to register a lucrative growth rate of 8.7% over the forecast period. The presence of an established generic industry and API providers in this region, coupled with the growing economic stability in some of the countries, is expected to propel market growth

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Country-wise market: Base estimates
  • 1.2 Global market: CAGR calculation
  • 1.3 Region based segment share calculation
  • 1.4 Research Scope & Assumptions
  • 1.5 List of Data Sources
    • 1.5.1 Data for primary interviews, by sources
    • 1.5.2 Data for primary interviews, by region

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Peptide Therapeutics Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
  • 3.2 Market Driver Analysis
    • 3.2.1 Increasing prevalence of cancer
    • 3.2.2 Rising incidences of metabolic disorder
    • 3.2.3 Presence of strong product pipeline portfolio
    • 3.2.4 Technological Advancement
  • 3.3 Market restraint analysis
    • 3.3.1 Stringent regulations
  • 3.4 Key Opportunities Prioritized
    • 3.4.1 Key opportunities prioritized
  • 3.5 Peptide Therapeutics Market - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.6 Industry Analysis - Porter's

Chapter 4 Peptide Therapeutics Market: Application Estimates & Trend Analysis

  • 4.1 Peptide Therapeutics market: Application movement analysis
  • 4.2 Cancer
    • 4.2.1 Cancer market, 2017 - 2030 (USD Million)
  • 4.3 Metabolic
    • 4.3.1 Metabolic market, 2017 - 2030 (USD Million)
  • 4.4 Cardiovascular Disorder
    • 4.4.1 Cardiovascular Disorder market, 2017 - 2030 (USD Million)
  • 4.5 Respiratory
    • 4.5.1 Respiratory market, 2017 - 2030 (USD Million)
  • 4.6 GIT
    • 4.6.1 GIT market, 2017 - 2030 (USD Million)
  • 4.7 Anti-infection
    • 4.7.1 Anti-infection market, 2017 - 2030 (USD Million)
  • 4.8 Pain
    • 4.8.1 Pain market, 2017 - 2030 (USD Million)
  • 4.9 Dermatology
    • 4.9.1 Dermatology market, 2017 - 2030 (USD Million)
  • 4.10 CNS
    • 4.10.1 CNS market, 2017 - 2030 (USD Million)
  • 4.11 Renal
    • 4.11.1 Renal market, 2017 - 2030 (USD Million)
  • 4.12 Others
    • 4.12.1 Others market, 2017 - 2030 (USD Million)

Chapter 5 Peptide Therapeutics Market: Type Estimates & Trend Analysis

  • 5.1 Peptide Therapeutics market: Type movement analysis
  • 5.2 Generic
    • 5.2.1 Generic Market, 2017 - 2030 (USD Million)
  • 5.3 Innovative
    • 5.3.1 Innovative Market, 2017 - 2030 (USD Million)

Chapter 6 Peptide Therapeutics Market: Type of Manufacturers Estimates & Trend Analysis

  • 6.1 Peptide Therapeutics market: Type of Manufacturers movement analysis
  • 6.2 In-house
    • 6.2.1 In-house market, 2017 - 2030 (USD Million)
  • 6.3 Outsourced
    • 6.3.1 Outsourced market, 2017 - 2030 (USD Million)

Chapter 7 Peptide Therapeutics Market Route of Administration Estimates & Trend Analysis

  • 7.1 Peptide Therapeutics market: Route of Administration movement analysis
  • 7.2 Parenteral
    • 7.2.1 Parenteral market, 2017 - 2030 (USD Million)
  • 7.3 Oral
    • 7.3.1 Oral market, 2017 - 2030 (USD Million)
  • 7.4 Pulmonary
    • 7.4.1 Pulmonary market, 2017 - 2030 (USD Million)
  • 7.5 Mucosal
    • 7.5.1 Mucosal market, 2017 - 2030 (USD Million)
  • 7.6 Others
    • 7.6.1 Others market, 2017 - 2030 (USD Million)

Chapter 8 Peptide Therapeutics Market Synthesis Technology Estimates & Trend Analysis

  • 8.1 Peptide Therapeutics market: Synthesis Technology movement analysis
  • 8.2 Solid Phase Peptide Synthesis (SPPS)
    • 8.2.1 Solid Phase Peptide Synthesis (SPPS) market, 2017 - 2030 (USD Million)
  • 8.3 Liquid Phase Peptide Synthesis (LPPS)
    • 8.3.1 Liquid Phase Peptide Synthesis (LPPS) market, 2017 - 2030 (USD Million)
  • 8.4 Hybrid Technology
    • 8.4.1 Hybrid Technology market, 2017 - 2030 (USD Million)

Chapter 9 Peptide Therapeutics Market: Regional Estimates & Trend Analysis, by Source, Product, Application

  • 9.1 Peptide Therapeutics market share by region, 2021 & 2030
  • 9.2 North America
    • 9.2.1 North America Peptide Therapeutics market, 2017 - 2030 (USD Million)
    • 9.2.2 U.S.
      • 9.2.2.1 U.S. Peptide Therapeutics market, 2017 - 2030 (USD Million)
    • 9.2.3 Canada
      • 9.2.3.1 Canada Peptide Therapeutics market, 2017 - 2030 (USD Million)
  • 9.3 Europe
    • 9.3.1 Europe Peptide Therapeutics market, 2017 - 2030 (USD Million)
    • 9.3.2 U.K.
      • 9.3.2.1 U.K. Peptide Therapeutics market, 2017 - 2030 (USD Million)
    • 9.3.3 Germany
      • 9.3.3.1 Germany Peptide Therapeutics market, 2017 - 2030 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Peptide Therapeutics market, 2017 - 2030 (USD Million)
    • 9.4.2 Japan
      • 9.4.2.1 Japan Peptide Therapeutics market, 2017 - 2030 (USD Million)
    • 9.4.3 China
      • 9.4.3.1 China Peptide Therapeutics market, 2017 - 2030 (USD Million)
    • 9.4.4 India
      • 9.4.4.1 India Peptide Therapeutics market, 2017 - 2030 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Latin America Peptide Therapeutics market, 2017 - 2030 (USD Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Brazil Peptide Therapeutics market, 2017 - 2030 (USD Million)
    • 9.5.3 Mexico
      • 9.5.3.1 Mexico Peptide Therapeutics market, 2017 - 2030 (USD Million)
  • 9.6 MEA
    • 9.6.1 MEA Peptide Therapeutics market, 2017 - 2030 (USD Million)
    • 9.6.2 South Africa
      • 9.6.2.1 South Africa Peptide Therapeutics market, 2017 - 2030 (USD Million)

Chapter 10 Competitive Landscape

  • 10.1 Strategy Framework
  • 10.2 Market Participation
  • 10.3 Company Profiles
    • 10.3.1 Bachem Holding AG
      • 10.3.1.1 Company overview
      • 10.3.1.2 Financial performance
      • 10.3.1.3 Product benchmarking
      • 10.3.1.4 Strategic initiatives
    • 10.3.2 Eli Lilly and Company
      • 10.3.2.1 Company overview
      • 10.3.2.2 Financial performance
      • 10.3.2.3 Product benchmarking
      • 10.3.2.4 Strategic initiatives
    • 10.3.3 Pfizer Inc.
      • 10.3.3.1 Company overview
      • 10.3.3.2 Financial performance
      • 10.3.3.3 Product benchmarking
      • 10.3.3.4 Strategic initiatives
    • 10.3.4 Amgen Inc.
      • 10.3.4.1 Company overview
      • 10.3.4.2 Financial performance
      • 10.3.4.3 Product benchmarking
      • 10.3.4.4 Strategic initiatives
    • 10.3.5 Takeda Pharmaceutical Company Limited
      • 10.3.5.1 Company overview
      • 10.3.5.2 Financial performance
      • 10.3.5.3 Product benchmarking
      • 10.3.5.4 Strategic initiatives
    • 10.3.6 Teva Pharmaceutical
      • 10.3.6.1 Company overview
      • 10.3.6.2 Financial performance
      • 10.3.6.3 Product benchmarking
      • 10.3.6.4 Strategic initiatives
    • 10.3.7 Lonza Inc.
      • 10.3.7.1 Company overview
      • 10.3.7.2 Financial performance
      • 10.3.7.3 Product benchmarking
      • 10.3.7.4 Strategic initiatives
    • 10.3.8 Sanofi
      • 10.3.8.1 Company overview
      • 10.3.8.2 Financial performance
      • 10.3.8.3 Product benchmarking
      • 10.3.8.4 Strategic initiatives
    • 10.3.9 Bristol-Myers Squibb(BMS)
      • 10.3.9.1 Company overview
      • 10.3.9.2 Financial performance
      • 10.3.9.3 Product benchmarking
      • 10.3.9.4 Strategic initiatives
    • 10.3.10 AstraZeneca PLC
      • 10.3.10.1 Company overview
      • 10.3.10.2 Financial performance
      • 10.3.10.3 Product benchmarking
      • 10.3.10.4 Strategic initiatives
    • 10.3.11 GlaxoSmithKline (GSK)
      • 10.3.11.1 Company overview
      • 10.3.11.2 Financial performance
      • 10.3.11.3 Product benchmarking
      • 10.3.11.4 Strategic initiatives
    • 10.3.12 Novartis AG
      • 10.3.12.1 Company overview
      • 10.3.12.2 Financial performance
      • 10.3.12.3 Product benchmarking
      • 10.3.12.4 Strategic initiatives
    • 10.3.13 Novo Nordisk A/S
      • 10.3.13.1 Company overview
      • 10.3.13.2 Financial performance
      • 10.3.13.3 Product benchmarking
      • 10.3.13.4 Strategic initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제